Skip to main content
NCBI home page
The BMJ logoLink to The BMJ
. 1993 Jun 12;306(6892):1584–1586. doi: 10.1136/bmj.306.6892.1584

Uptake of cystic fibrosis testing in primary care: supply push or demand pull?

H Bekker 1, M Modell 1, G Denniss 1, A Silver 1, C Mathew 1, M Bobrow 1, T Marteau 1
PMCID: PMC1678014  PMID: 8329922

Abstract

OBJECTIVE--To determine the acceptability and feasibility of screening for carriers of cystic fibrosis in a primary care setting. DESIGN--Follow up study over 15 months of patients offered carrier testing by mouthwash. SETTING--A general practice in inner London. SUBJECTS--5529 patients aged 18-45 invited by various methods and combinations of methods (letter, booklet, personal approach) for testing. MAIN OUTCOME MEASURES--Uptake of screening, anxiety, and knowledge of test. RESULTS--957 (17%) invitees were screened over the 15 months. 28 carriers and no carrier couples were detected. Uptake rates were 12% (59/502 patients) among patients invited by letter and tested by appointment; 9% (47/496) among patients invited by letter, with leaflet, and tested by appointment; 4% (128/2953) among patients invited by letter six weeks before the end of the study and tested by appointment; 17% (81/471) among patients offered passive opportunistic testing; 70% (453/649) among patients offered active opportunistic testing; and 25% (22/88) among patients offered active opportunistic testing by appointment. A short term rise in anxiety among those given a positive test result had dissipated by three months. At three months about one fifth and one third of those given positive and negative results respectively did not understand their results correctly. CONCLUSION--These results suggest that the strongest variable in determining uptake of screening is the active approach by a health professional offering immediate testing. It remains to be resolved whether the high uptake rates achieved by active recruitment indicate a supply push for this new test rather than a demand from the population.

Full text

PDF
1584

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bak-Christensen A., Dimo B., Samson D., Wille-Jørgensen P. Cutaneous reactions in relation to the use of 'TED'-stockings. Lancet. 1989 Dec 2;2(8675):1346–1346. doi: 10.1016/s0140-6736(89)91962-4. [DOI] [PubMed] [Google Scholar]
  2. Cheadle J., Myring J., al-Jader L., Meredith L. Mutation analysis of 184 cystic fibrosis families in Wales. J Med Genet. 1992 Sep;29(9):642–646. doi: 10.1136/jmg.29.9.642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ferrie R. M., Schwarz M. J., Robertson N. H., Vaudin S., Super M., Malone G., Little S. Development, multiplexing, and application of ARMS tests for common mutations in the CFTR gene. Am J Hum Genet. 1992 Aug;51(2):251–262. [PMC free article] [PubMed] [Google Scholar]
  4. Flinter F. A., Silver A., Mathew C. G., Bobrow M. Population screening for cystic fibrosis. Lancet. 1992 Jun 20;339(8808):1539–1540. doi: 10.1016/0140-6736(92)91304-q. [DOI] [PubMed] [Google Scholar]
  5. Kerem B., Rommens J. M., Buchanan J. A., Markiewicz D., Cox T. K., Chakravarti A., Buchwald M., Tsui L. C. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989 Sep 8;245(4922):1073–1080. doi: 10.1126/science.2570460. [DOI] [PubMed] [Google Scholar]
  6. Lench N., Stanier P., Williamson R. Simple non-invasive method to obtain DNA for gene analysis. Lancet. 1988 Jun 18;1(8599):1356–1358. doi: 10.1016/s0140-6736(88)92178-2. [DOI] [PubMed] [Google Scholar]
  7. Marteau T. M., Bekker H. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol. 1992 Sep;31(Pt 3):301–306. doi: 10.1111/j.2044-8260.1992.tb00997.x. [DOI] [PubMed] [Google Scholar]
  8. Mennie M. E., Gilfillan A., Compton M., Curtis L., Liston W. A., Pullen I., Whyte D. A., Brock D. J. Prenatal screening for cystic fibrosis. Lancet. 1992 Jul 25;340(8813):214–216. doi: 10.1016/0140-6736(92)90476-j. [DOI] [PubMed] [Google Scholar]
  9. Ng I. S., Pace R., Richard M. V., Kobayashi K., Kerem B., Tsui L. C., Beaudet A. L. Methods for analysis of multiple cystic fibrosis mutations. Hum Genet. 1991 Sep;87(5):613–617. doi: 10.1007/BF00209023. [DOI] [PubMed] [Google Scholar]
  10. Riordan J. R., Rommens J. M., Kerem B., Alon N., Rozmahel R., Grzelczak Z., Zielenski J., Lok S., Plavsic N., Chou J. L. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989 Sep 8;245(4922):1066–1073. doi: 10.1126/science.2475911. [DOI] [PubMed] [Google Scholar]
  11. Rommens J. M., Iannuzzi M. C., Kerem B., Drumm M. L., Melmer G., Dean M., Rozmahel R., Cole J. L., Kennedy D., Hidaka N. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science. 1989 Sep 8;245(4922):1059–1065. doi: 10.1126/science.2772657. [DOI] [PubMed] [Google Scholar]
  12. Shoshani T., Augarten A., Gazit E., Bashan N., Yahav Y., Rivlin Y., Tal A., Seret H., Yaar L., Kerem E. Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease. Am J Hum Genet. 1992 Jan;50(1):222–228. [PMC free article] [PubMed] [Google Scholar]
  13. Shrimpton A. E., McIntosh I., Brock D. J. The incidence of different cystic fibrosis mutations in the Scottish population: effects on prenatal diagnosis and genetic counselling. J Med Genet. 1991 May;28(5):317–321. doi: 10.1136/jmg.28.5.317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Super M., Schwarz M. J., Malone G. Screening for cystic fibrosis carriers. Lancet. 1992 Aug 22;340(8817):490–491. doi: 10.1016/0140-6736(92)91816-q. [DOI] [PubMed] [Google Scholar]
  15. Ten Kate L. P., Tijmstra T. Community attitudes to cystic fibrosis carrier screening. Prenat Diagn. 1990 Apr;10(4):275–276. doi: 10.1002/pd.1970100413. [DOI] [PubMed] [Google Scholar]
  16. Tsui L. C. The spectrum of cystic fibrosis mutations. Trends Genet. 1992 Nov;8(11):392–398. doi: 10.1016/0168-9525(92)90301-j. [DOI] [PubMed] [Google Scholar]
  17. Watson E. K., Mayall E. S., Lamb J., Chapple J., Williamson R. Psychological and social consequences of community carrier screening programme for cystic fibrosis. Lancet. 1992 Jul 25;340(8813):217–220. doi: 10.1016/0140-6736(92)90477-k. [DOI] [PubMed] [Google Scholar]
  18. Watson E. K., Mayall E., Chapple J., Dalziel M., Harrington K., Williams C., Williamson R. Screening for carriers of cystic fibrosis through primary health care services. BMJ. 1991 Aug 31;303(6801):504–507. doi: 10.1136/bmj.303.6801.504. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Wilfond B. S., Fost N. The cystic fibrosis gene: medical and social implications for heterozygote detection. JAMA. 1990 May 23;263(20):2777–2783. [PubMed] [Google Scholar]
  20. Williamson R., Allison M. E., Bentley T. J., Lim S. M., Watson E., Chapple J., Adam S., Boulton M. Community attitudes to cystic fibrosis carrier testing in England: a pilot study. Prenat Diagn. 1989 Oct;9(10):727–734. doi: 10.1002/pd.1970091008. [DOI] [PubMed] [Google Scholar]

Articles from BMJ : British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES